Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M19.4Revenue (TTM) $M14.9Net Margin (%)-102.4Altman Z-Score-29.5
Enterprise Value $M7.4EPS (TTM) $-5.5Operating Margin %-104.3Piotroski F-Score3
P/E(ttm)--Beneish M-Score27.3Pre-tax Margin (%)-102.3Higher ROA y-yY
Price/Book6.910-y EBITDA Growth Rate %--Quick Ratio1.8Cash flow > EarningsN
Price/Sales0.55-y EBITDA Growth Rate %--Current Ratio1.8Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-67.7Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-314.5Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M6.3ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with ONTX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ONTXGeorge Soros 2014-09-30 Sold Out $43 - $56.4
($50.59)
$ 3.06-94%Sold Out0
ONTXGeorge Soros 2014-06-30 Buy $41.8 - $63.4
($52.63)
$ 3.06-94%New holding108
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ONTX is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


ONTX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Michael & Jane Hoffman 2013 De10% Owner 2014-02-21Buy14,348$84.7-96.39view
Hoffman Michael BDirector, 10% Owner 2014-02-21Buy14,348$84.7-96.39view
Kumar RameshPresident and CEO 2014-02-10Sell3,354$150.7-97.97view
Kumar RameshPresident and CEO 2014-02-03Sell6,000$150.5-97.97view
Hoffman Michael BDirector, 10% Owner 2014-01-27Buy5,730$119.2-97.43view
Michael & Jane Hoffman 2013 De10% Owner 2014-01-27Buy5,730$119.2-97.43view
Michael & Jane Hoffman 2013 De10% Owner 2013-11-22Buy500$143.9-97.87view
Hoffman Michael BDirector, 10% Owner 2013-11-22Buy500$143.9-97.87view
Reddy E PremkumarDirector 2013-11-18Buy500$121-97.47view
Hoffman Michael BDirector, 10% Owner 2013-11-18Buy500$118.7-97.42view

Quarterly/Annual Reports about ONTX:

    News about ONTX:

    Articles On GuruFocus.com
    Weekly 3-Year Low Highlights: VCRA, CLUB, ARGS, ONTX, BOTA Jun 08 2014 

    More From Other Websites
    7:03 am Onconova Therapeutics announces receipt of the End-of-Phase 2 meeting minutes from the FDA... Sep 26 2016
    Onconova Announces Successful End-of-Phase 2 Meeting with FDA for Oral Rigosertib and Azacitidine... Sep 26 2016
    Onconova Therapeutics, Inc. to Present Corporate Updates at Upcoming Investor Conferences Sep 07 2016
    Onconova Therapeutics, Inc. to Present Corporate Updates at Upcoming Investor Conferences Sep 07 2016
    More job cuts at Bucks County biopharm firm Sep 01 2016
    ONCONOVA THERAPEUTICS, INC. Files SEC form 8-K, Costs Associated with Exit or Disposal Activities,... Aug 30 2016
    ETF’s with exposure to Onconova Therapeutics, Inc. : August 30, 2016 Aug 30 2016
    ONCONOVA THERAPEUTICS, INC. Financials Aug 23 2016
    ETF’s with exposure to Onconova Therapeutics, Inc. : August 19, 2016 Aug 19 2016
    5 Breakout Stocks Under $10 Set to Soar Aug 18 2016
    Onconova Therapeutics, Inc. :ONTX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 18, 2016 Aug 18 2016
    ONCONOVA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 15 2016
    Onconova Therapeutics, Inc. Reports Recent Business Highlights and Second Quarter 2016 Financial... Aug 15 2016
    Onconova Therapeutics, Inc. Reports Recent Business Highlights and Second Quarter 2016 Financial... Aug 15 2016
    7 Stocks Under $10 Making Big Up Moves Aug 12 2016
    Onconova Therapeutics, Inc. Announces Timing for Second Quarter 2016 Financial Results Aug 11 2016
    Onconova Therapeutics, Inc. Announces Timing for Second Quarter 2016 Financial Results Aug 11 2016
    Onconova Closes Oversubscribed Rights Offering with Gross Proceeds of $17.4 Million Aug 01 2016
    Onconova Closes Oversubscribed Rights Offering with Gross Proceeds of $17.4 Million Aug 01 2016
    Onconova Announces Expiration of Oversubscribed Rights Offering Jul 27 2016
    Onconova Announces Expiration of Oversubscribed Rights Offering Jul 27 2016
    Onconova Adjusts Pricing of Rights Offering Jul 22 2016
    Onconova Adjusts Pricing of Rights Offering Jul 22 2016
    Onconova Announces Enrollment of First Patient in Japan by SymBio Jul 19 2016
    ONCONOVA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jul 13 2016
    Onconova Announces Commencement of Subscription Period for Previously Announced Rights Offering Jul 08 2016
    Onconova Announces Commencement of Subscription Period for Previously Announced Rights Offering Jul 08 2016
    Onconova Reminds Shareholders That Rights Offering Ownership Day is Friday, July 1, 2016 Jul 01 2016
    Onconova Reminds Shareholders That Rights Offering Ownership Day is Friday, July 1, 2016 Jul 01 2016
    Onconova Announces Price Range and Change of Key Dates for Rights Offering Jun 29 2016
    Onconova Announces Price Range and Change of Key Dates for Rights Offering Jun 29 2016
    Onconova Presents Clinical Data from Oral Rigosertib and Azacitidine Combination Study in... Jun 13 2016
    Onconova Announces Presentations Highlighting IV Rigosertib and Oral Rigosertib/Azacitidine... Jun 06 2016
    Onconova Files S-1 Registration Statement for Rights Offering to Shareholders Jun 01 2016
    Onconova Announces Upcoming Presentations Related to Advanced Rigosertib Clinical Trials at 2016... May 31 2016
    Onconova Therapeutics, Inc. Announces Appointment of Jack E. Stover to Board of Directors May 23 2016
    Onconova Therapeutics, Inc. Announces Results of Annual Meeting, Effective Date of One-For-Ten... May 20 2016
    Onconova Therapeutics, Inc. Reports Recent Business Highlights and First Quarter 2016 Financial... May 11 2016
    Onconova Announces Publication Describing Unique RAS-targeted Mechanism of Action for Rigosertib in... Apr 21 2016
    Onconova Announces Novel Dual Targeting of ARK5 and CDK4/6 by Pre-clinical Compound, ON 123300, in... Apr 20 2016
    Onconova Therapeutics, Inc. Reports Recent Business Highlights and Year-end 2015 Financial Results Mar 28 2016
    Onconova Enrolls First Patient in Europe for Phase 3 INSPIRE Trial of Rigosertib in Higher-Risk... Mar 21 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)